Strides Pharma Science Ltd
NSE: STAR BSE: 532531
₹893.95
(2.41%)
Thu, 12 Mar 2026, 01:05 am
Market Cap80.39B
PE Ratio16.11
Dividend0.46
Health Technology
Pharmaceuticals: Major
24.5KStrides Pharma Science Analysis
dividend
- Dividends per share have increased over the past 10 years.
- Dividends paid are well covered by earnings (2.7x coverage).
- Dividends after 3 years are expected to be thoroughly covered by earnings (9.1x coverage).
- Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
- Strides Pharma Science's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
- Strides Pharma Science's dividend is below the markets top 25% of dividend payers in India (3.08%).
future
- Cash flow for Strides Pharma Science is expected to increase by more than 50% in 2 years time.
- Strides Pharma Science's earnings are expected to grow significantly at over 20% yearly.
- Strides Pharma Science's earnings growth is expected to exceed the India market average.
- Strides Pharma Science's earnings growth is expected to exceed the low risk savings rate of 7.2%.
- Strides Pharma Science's earnings are expected to exceed the low risk growth rate next year.
- Strides Pharma Science's earnings are expected to increase by more than the low risk growth rate in 3 years time.
- Strides Pharma Science's net income is expected to increase by more than 50% in 2 years time.
- An improvement in Strides Pharma Science's performance (ROE) is expected over the next 3 years.
- Strides Pharma Science's revenue growth is expected to exceed the India market average.
- Strides Pharma Science is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
- Performance (ROE) is not expected to exceed the current IN Pharmaceuticals industry average.
- Strides Pharma Science's revenue is expected to increase but not above the 50% threshold in 2 years time.
- Strides Pharma Science's revenue is expected to grow by 12.4% yearly, however this is not considered high growth (20% yearly).
health
- Strides Pharma Science is profitable, therefore cash runway is not a concern.
- Strides Pharma Science is profitable, therefore cash runway is not a concern.
- Debt is covered by short term assets, assets are 1.3x debt.
- Strides Pharma Science's cash and other short term assets cover its long term commitments.
- The level of debt compared to net worth has been reduced over the past 5 years (76.6% vs 70.6% today).
- Strides Pharma Science's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
- Debt is not well covered by operating cash flow (11.2%, less than 20% of total debt).
- Interest payments on debt are not well covered by earnings (EBIT is 2.3x annual interest expense, ideally 3x coverage).
- Strides Pharma Science's level of debt (70.6%) compared to net worth is high (greater than 40%).
- High level of physical assets or inventory.
management
- The tenure for the Strides Pharma Science board of directors is about average.
- The tenure for the Strides Pharma Science management team is about average.
misc
- Strides Pharma Science has significant price volatility in the past 3 months.
past
- Strides Pharma Science has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
- Strides Pharma Science's 1-year earnings growth is negative, it can't be compared to the 5-year average.
- Strides Pharma Science's year on year earnings growth rate was negative over the past 5 years and the most recent earnings are below average.
- Strides Pharma Science used its assets less efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Strides Pharma Science has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
- Strides Pharma Science's 1-year earnings growth is negative, it can't be compared to the IN Pharmaceuticals industry average.
value
- Strides Pharma Science's share price is below the future cash flow value, and at a moderate discount (> 20%).
- Strides Pharma Science's share price is below the future cash flow value, and at a substantial discount (> 40%).
- Strides Pharma Science is good value based on assets compared to the IN Pharmaceuticals industry average.
- 532531 outperformed the Market in India which returned -14.5% over the past year.
- Strides Pharma Science is poor value based on expected growth next year.
- Strides Pharma Science is overvalued based on earnings compared to the IN Pharmaceuticals industry average.
- Strides Pharma Science is overvalued based on earnings compared to the India market.
- 532531 underperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- BSE:532531 is down -5.1% underperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- BSE:532531 is down -5.1% underperforming the market in India which returned 8% over the past month.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800